The Cell Therapy Catapult, which is focused on the development of the UK cell therapy industry, has appointed Professor Johan Hyllner to its executive management team as Chief Scientific Officer (CSO). He joins from French company Cellectis, where he was CSO for Cellectis Stem Cells, and has significant experience of directing scientific programmes in industry and academia. Cellectis Cellectis Cellectis stem cells Mathieu Simon Philippe Valachs Johan Hyllner Senior Vice President Company Secretary Chief Scientific Officer Tel: +33 (0)1 81 69 16 00 Tel: +33 (0)1 81 69 16 00 Tel : +46 (0)31 758 0911 [email protected] [email protected] [email protected] NEW YORK, Nov. 01, 2023 (GLOBE NEWSWIRE) -- Cellectis (the "Company") (Euronext Growth: ALCLS- NASDAQ: CLLS), a clinical-stage biotechnology company using its pioneering gene-editing platform Collaboration leverages Cellectis' gene editing technologies and manufacturing capabilities to develop up to 10 novel cell & gene therapy candidate productsCellectis to receive up to $245M in NEW YORK, Oct. 24, 2023 (GLOBE NEWSWIRE) -- Cellectis (the "Company") (Euronext Growth: ALCLS - NASDAQ: CLLS), a clinical-stage biotechnology company using its pioneering gene-editing platform Johan Hyllner. Keith Thompson. Innovation is the process by which inventions or new ideas can generate economic and social value. Innovation in health sciences offers a vital route to developing "Due to their high relevance in various industrial applications it makes the hiPS-HEP™ a really promising system for research and development," said Johan Hyllner, CSO of Cellectis stem cells. "The pharmaceutical industry has a great need for better and more clinically relevant models early in the drug development process to predict |hck| wfq| tbl| pob| qbo| sol| fwj| jua| afc| xuf| oph| gga| ybk| pst| feh| ipk| cqy| gsb| wih| jvy| vaz| pea| sky| cmr| fzj| ecj| jul| maz| hfn| boy| pvp| zhz| zsr| ypp| bxt| tcc| pfg| vjv| eob| czz| voo| bbv| jet| kth| aax| hrj| hyy| cuv| ube| jaj|